文献速递药疹与重症皮肤不良反应皮肤肿瘤

PD-1/PD-L1抑制剂治疗后皮炎的特征及其与多种肿瘤结局的关联:一项回顾性病例对照研究

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
PubMed 文献 · J Am Acad Dermatol · 2018-05-29

该单中心回顾性匹配病例对照研究评估PD-1/PD-L1抑制剂治疗后皮炎的组织学特征及肿瘤结局。最常见组织学模式为苔藓样皮炎(50%)和海绵水肿性皮炎(40%)。病例组总体肿瘤缓解率为65.0%,对照组为17.0%(P=0.0007;OR=7.3;95%CI 2.3-23.1)。Kaplan-Meier分析显示病例组无进展生存期和总生存期均显著长于对照组(P<0.0001和P=0.0203)。

要点

  • PD-1/PD-L1抑制剂相关皮炎最常见组织学模式为苔藓样皮炎(50%)和海绵水肿性皮炎(40%)。
  • 病例组总体肿瘤缓解率65.0% vs 对照组17.0%(P=0.0007;OR=7.3;95%CI 2.3-23.1)。
  • 病例组无进展生存期和总生存期均显著长于对照组(P<0.0001和P=0.0203)。

核心结论

  • PD-1/PD-L1抑制剂相关的苔藓样和海绵水肿性皮炎可能是强免疫应答和肿瘤结局改善的标志。
  • PD-1/PD-L1相关皮炎预测癌症结局的价值有待通过针对特定癌症类型的前瞻性多中心研究来验证。

研究设计与样本

  • 在单一学术中心开展的回顾性匹配病例对照研究。

主要发现

  • 最常见的组织学模式为苔藓样皮炎(50%)和海绵水肿性皮炎(40%)。
  • 病例组总体肿瘤缓解率为65.0%,对照组为17.0%(P=0.0007;OR=7.3;95%CI 2.3-23.1)。
  • Kaplan-Meier分析显示病例组无进展生存期和总生存期均显著长于对照组(P<0.0001和P=0.0203)。

局限性

  • 回顾性设计和相对较小的样本量导致无法对所有癌症类型进行匹配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous adverse events are common with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors. However, the nature of the specific cutaneous adverse event of dermatitis has not been investigated across various PD-1/PD-L1 inhibitors. Oncologic outcomes potentially associated with dermatitis are not well characterized. OBJECTIVE: To assess the nature of dermatitis after exposure to a PD-1/PD-L1 inhibitor and oncologic outcomes associated with dermatitis. METHODS: Retrospective, matched, case-control study conducted at a single academic center. RESULTS: The most common histologic patterns were lichenoid dermatitis (50%) and spongiotic dermatitis (40%). The overall tumor response rate was 65.0% for the case patients and 17.0% for the controls (P = .0007) (odds ratio, 7.3; 95% confidence interval, 2.3-23.1). The progression-free survival and overall survival times were significantly longer for the case patients than for the controls by Kaplan-Meier analysis (P < .0001 and .0203, respectively). LIMITATIONS: The retrospective design and relatively small sample size precluded matching for all cancer types. CONCLUSIONS: Lichenoid and spongiotic dermatitis associated with PD-1/PD-L1 inhibitors could be a sign of robust immune response and improved oncologic outcomes. The value of PD-1/PD-L1-related dermatitis in predicting cancer outcomes awaits investigation through prospective multicenter studies for specific cancer types.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. J Am Acad Dermatol. 2018. PMID: 29857011. doi:10.1016/j.jaad.2018.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。